Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

News Feb 2, 2010 Nektar Therapeutics Appoints R. Scott Greer to Board of Directors » Jan 12, 2010 Nektar Therapeutics Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer » Jan 6, 2010 Nektar Therapeutics Names Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer » Jan 6, 2010 Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco, CA »

Contact Nektar investor relations Jennifer Ruddock Vice President of Investor Relations and Corporate Affairs 650-631-4954 Contact